Merck KGAA: Reinventing the Mid-Sized Public Company
Merck's goal is to build a leading position in specialty OTCs as well as a worldwide generics business, both goals designed to offset the risks of its R&D program. Its new business allows it to use its size as an advantage against smaller, specialized players while avoiding direct competition with the larger multinationals.
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.